Mass Innovation Labs Launches 124,000ft2 Co-working Lab Space in Kendall Square

--Partners with Charles River Laboratories to Provide World-class Accelerated Commercialization Space--

--Announces CRISPR Therapeutics as First Tenant--

CAMBRIDGE, Mass.--()--Mass Innovation Labs today announced the launch of 124,000 square foot accelerated commercialization space (ACS) in the heart of Kendall Square. An ACS is designed to provide comprehensive solutions for growing life science companies, including research model facilities, co-located CRO services, and operational needs under one roof. Mass Innovation Labs is comprised of first-class chemistry and biology laboratories alongside office space and is located at 675 West Kendall St. in Cambridge, Massachusetts.

“We believe that we are at the forefront of an evolving research landscape, where innovators are seeking a collaborative ecosystem that allows them to run as a lean organization and focus on the science with expert drug development partners down the hall”

“We believe that we are at the forefront of an evolving research landscape, where innovators are seeking a collaborative ecosystem that allows them to run as a lean organization and focus on the science with expert drug development partners down the hall,” said Amrit Chaudhuri, CEO of Mass Innovation Labs. “By co-locating the resources a company needs from idea inception through commercialization, we facilitate troubleshooting and drive brilliant execution. Mass Innovation Labs is a space for life science companies of all shapes and sizes to grow, innovate and succeed in commercializing the next breakthrough.”

One of the Company’s partners, Charles River Laboratories, recently opened Charles River Accelerator and Development Lab (CRADL™), an onsite turnkey facility to provide customized vivarium space and scientific support. CRADL offers a flexible option for biopharmaceutical companies to launch or expand research capabilities, with the added benefit of access to Charles River’s premier portfolio of integrated drug discovery resources.

“Charles River’s partnership with Mass Innovation Labs creates a flexible and customizable solution for our biopharmaceutical clients who are launching or expanding research capabilities,” said Greg Beattie, Corporate Vice President of Insourcing Solutions and Research Support Services. “As our clients increasingly choose outsourcing as a means to improve the effectiveness and efficiency of their early-stage drug research efforts, CRADL provides scientific expertise and start-of-the-art capacity, which enable biopharmaceutical companies to focus on their research, with the goal of bringing innovative, life-saving therapies to market.”

CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines for serious human diseases, is the first tenant to join Mass Innovation Labs and CRADL.

“The turnkey operational support from Mass Innovation Labs enables us to get up and running quickly, expand our team and focus on hitting key milestones as we make headway on our breakthrough approach in gene-editing, CRISPR-Cas9,” commented Dr. Bill Lundberg, Chief Scientific Officer of CRISPR Therapeutics.

About Mass Innovation Labs

Mass Innovation Labs embodies an ecosystem of innovators in its 124,000ft2 first-class chemistry and biology space in the heart of Kendall Square. We provide comprehensive solutions for growing companies, including animal facilities, co-located CRO services and operational needs. Our goal is to reduce the time for teams to overcome hurdles on their way to a milestone. www.massinnovationlabs.com

Contacts

MacDougall Biomedical Communications
Karen Sharma, 781-235-3060
ksharma@macbiocom.com
or
Michelle Avery, 781-235-3060
mavery@macbiocom.com

Release Summary

Mass Innovation Labs announce the launch of 124,000 square foot accelerated commercialization space (ACS) designed to provide comprehensive solutions for growing life science companies.

Mass Innovation Labs